Network Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity

References

• KimCA, SpratlinJL, ArmstrongDE, et al. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience. Clin Colorectal Cancer. 2014;13(3):199‐206. doi:10.1016/j.clcc.2014.06.002
   Web of Science ®Google Scholar
• XiaoWH, ZhengH, BennettGJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012;203:194‐206. doi:10.1016/j.neuroscience.2011.12.023
   Web of Science ®Google Scholar
• HanCH, KilfoyleDH, HillAG, et al. Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. Expert Opin Drug Metab Toxicol. 2016;12(12):1479‐1490. doi:10.1080/17425255.2016.1223625
   Web of Science ®Google Scholar
• HuS, HuangKM, AdamsEJ, et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2019;25(21):6295‐6301. doi:10.1158/1078-0432.CCR-18-2152
   Web of Science ®Google Scholar
• AuyeungKK, HanQB, KoJK. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers. Am J Chin Med. 2016;44(1):1‐22. doi:10.1142/S0192415X16500014
   Web of Science ®Google Scholar
• KimS, KangIH, NamJB, et al. Ameliorating the effect of astragaloside IV on learning and memory deficit after chronic cerebral hypoperfusion in rats. Molecules. 2015;20(2):1904‐1921. doi:10.3390/molecules20021904
   Web of Science ®Google Scholar
• YangP, ZhouY, XiaQ, et al. Astragaloside IV regulates the PI3K/Akt/HO-1 signaling pathway and inhibits H9c2 cardiomyocyte injury induced by hypoxia-reoxygenation. Biol Pharm Bull. 2019;42(5):721‐727. doi:10.1248/bpb.b18-00854
   Web of Science ®Google Scholar
• YeQ, SuL, ChenD, et al. Astragaloside IV induced miR-134 expression reduces EMT and increases chemotherapeutic sensitivity by suppressing CREB1 signaling in colorectal cancer cell line SW-480. Cell Physiol Biochem. 2017;43(4):1617‐1626. doi:10.1159/000482025
   Google Scholar
• WangS, MouJ, CuiL, et al. Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3. Biomed Pharmacother. 2018;102:1037‐1044. doi:10.1016/j.biopha.2018.03.127
   Web of Science ®Google Scholar
• ZhuJ, WenK. Astragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells. Phytother Res. 2018;32(7):1289‐1296. doi:10.1002/ptr.6057
   Web of Science ®Google Scholar
• ZhuB, ZhangW, LuY, et al. Network pharmacology-based identification of protective mechanism of panax notoginseng saponins on aspirin induced gastrointestinal injury. Biomed Pharmacother. 2018;105:159‐166. doi:10.1016/j.biopha.2018.04.054
   Web of Science ®Google Scholar
• HolmesJ, StankoJ, VarchenkoM, et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a wistar rat model. Toxicol Sci. 1998;46(2):342‐351. doi:10.1006/toxs.1998.2558
   Web of Science ®Google Scholar
• KawashiriT, EgashiraN, WatanabeH, et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain. 2011;15(4):344‐350. doi:10.1016/j.ejpain.2010.08.006
   Web of Science ®Google Scholar
• ArgyriouAA, PolychronopoulosP, IconomouG, et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34(4):368‐377. doi:10.1016/j.ctrv.2008.01.003
   Web of Science ®Google Scholar
• BalayssacD, FerrierJ, PereiraB, et al. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open. 2015;5(4):e007479. doi:10.1136/bmjopen-2014-007479
   PubMed Web of Science ®Google Scholar
• FuJ, WangZ, HuangL, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014;28(9):1275‐1283. doi:10.1002/ptr.5188
   Web of Science ®Google Scholar
• ZhangA, ZhengY, QueZ, et al. Astragaloside IV inhibits progression of lung cancer by mediating immune function of tregs and CTLs by interfering with IDO. J Cancer Res Clin Oncol. 2014;140(11):1883‐1890. doi:10.1007/s00432-014-1744-x
   Web of Science ®Google Scholar
• ChenM, MayBH, ZhouIW, et al. FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. Phytother Res. 2014;28(7):976‐991. doi:10.1002/ptr.5092
   Web of Science ®Google Scholar
• Di Cesare MannelliL, ZanardelliM, BartolucciG, et al. In vitro evidence for the use of astragali radix extracts as adjuvant against oxaliplatin-induced neurotoxicity. Planta Med. 2015;81(12–13):1045‐1055. doi:10.1055/s-0035-1546117
   Web of Science ®Google Scholar
• LiS, ZhangB. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110‐120. doi:10.1016/S1875-5364(13)60037-0
   Web of Science ®Google Scholar
• YuanH, MaQ, CuiH, et al. How can synergism of traditional medicines benefit from network pharmacology? Molecules. 2017;22(7):1135. doi:10.3390/molecules22071135
   PubMed Web of Science ®Google Scholar
• Hao daC, XiaoPG. Network pharmacology: a rosetta stone for traditional Chinese medicine. Drug Dev Res. 2014;75(5):299‐312. doi:10.1002/ddr.21214
   Web of Science ®Google Scholar
• RuJ, LiP, WangJ, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13. doi:10.1186/1758-2946-6-1324735618
   PubMed Web of Science ®Google Scholar
• GopalsamyB, FaroukAAO, Tengku MohamadTAS, SulaimanMR, PerimalEK. Antiallodynic and antihyperalgesic activities of zerumbone via the suppression of IL-1β, IL-6, and TNF-α in a mouse model of neuropathic pain. J Pain Res. 2017;10:2605‐2619. doi:10.2147/JPR.S143024
   Web of Science ®Google Scholar
• MuleyMM, KrustevE, ReidAR, McDougallJJ. Prophylactic inhibition of neutrophil elastase prevents the development of chronic neuropathic pain in osteoarthritic mice. J Neuroinflammation. 2017;14(1):168. doi:10.1186/s12974-017-0944-028835277
   PubMed Web of Science ®Google Scholar
• OgawaN, KawaiH, TerashimaT, et al. Gene therapy for neuropathic pain by silencing of TNF-α expression with lentiviral vectors targeting the dorsal root ganglion in mice. PLoS One. 2014;9(3):e92073. doi:10.1371/journal.pone.009207324642694
   PubMed Web of Science ®Google Scholar
• PacurariM, WaughS, KrajnakK. Acute vibration induces peripheral nerve sensitization in a rat tail model: possible role of oxidative stress and inflammation. Neuroscience. 2019;398:263‐272. doi:10.1016/j.neuroscience.2018.12.010
   Web of Science ®Google Scholar
• FlattersSJL, DoughertyPM, ColvinLA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth. 2017;119(4):737‐749. doi:10.1093/bja/aex229
   Web of Science ®Google Scholar
• KarlssonJOG, AnderssonRG, JyngeP. Mangafodipir a selective cytoprotectant - with special reference to oxaliplatin and its association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017;10(4):641‐649. doi:10.1016/j.tranon.2017.04.012
   Web of Science ®Google Scholar
• ZhangX, GuanZ, WangX, et al. Curcumin alleviates oxaliplatin-induced peripheral neuropathic pain through inhibiting oxidative stress-mediated activation of NF-κB and mitigating inflammation. Biol Pharm Bull. 2020;43(2):348‐355. doi:10.1248/bpb.b19-00862
   Web of Science ®Google Scholar